APO RESEARCH · REPORT
Hydroxyprogesterone Caproate Injection
Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton and Makena among others, is a progestin medication which is used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders.It has also been formulated in combination with estrogens for various indications (brand names Gravibinon and Primosiston) and as a form of long-lasting injectable birth control (brand name Chinese Injectable No. 1). It is not used by mouth and is instead given by injection into muscle or fat, typically once per week to once per month depending on the indication.
Product & engineering
Understand the product.
Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton and Makena among others, is a progestin medication which is used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders.It has also been formulated in combination with estrogens for various indications (brand names Gravibinon and Primosiston) and as a form of long-lasting injectable birth control (brand name Chinese Injectable No. 1). It is not used by mouth and is instead given by injection into muscle or fat, typically once per week to once per month depending on the indication.
Selected research
Industry Research
Hydroxyprogesterone Caproate Injection Industry Research Report 2026
Market perspective
Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton and Makena among others, is a progestin medication which is used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders.It has also been formulated in combination with estrogens for various indications (brand names Gravibinon and Primosiston) and as a form of long-lasting injectable birth control (brand name Chinese Injectable No. 1). It is not used by mouth and is instead given by injection into muscle or fat, typically once per week to once per month depending on the indication.
Global hydroxyprogesterone caproate injection main manufactuers include AMAG Pharmaceuticals, Mcguff Pharmaceuticals and Aspen, etc., totally holding a share for 97% of the market. North America is the largest market of hydroxyprogesterone caproate injection, with a share about 37%. As for the types of products, it can be divided into 1 ml injection(including 1.1 mL) and 5 ml injection. The most common product is 5 ml injection, with a share over 52%. In terms of applications, it is widely used in hospitals and clinics. The most commom application is in hospitals, with a share over 50%.
Report Scope
Read the full market overview
This report quantifies the global Hydroxyprogesterone Caproate Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hydroxyprogesterone Caproate Injection Market by Company
AMAG Pharmaceuticals
Mcguff Pharmaceuticals Inc
Aspen Oss B.V
American Regent, Inc.
Mylan Institutional
Hydroxyprogesterone Caproate Injection Segment by Type
1 mL Injection(Including 1.1 mL)
5 mL Injection
Hydroxyprogesterone Caproate Injection Segment by Application
Hospitals Injection
Clinics Injection
Hydroxyprogesterone Caproate Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hydroxyprogesterone Caproate Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hydroxyprogesterone Caproate Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hydroxyprogesterone Caproate Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hydroxyprogesterone Caproate Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hydroxyprogesterone Caproate Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hydroxyprogesterone Caproate Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 1 mL Injection(Including 1.1 mL)
- 5 mL Injection
Applications
- Hospitals Injection
- Clinics Injection
Companies covered
- AMAG Pharmaceuticals
- Mcguff Pharmaceuticals Inc
- Aspen Oss B.V
- American Regent, Inc.
- Mylan Institutional
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hydroxyprogesterone Caproate Injection Market Size (2021-2032)
- 2.2.2 Global Hydroxyprogesterone Caproate Injection Sales (2021-2032)
- 2.2.3 Global Hydroxyprogesterone Caproate Injection Market Average Price (2021-2032)
- 2.3 Hydroxyprogesterone Caproate Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 1 mL Injection(Including 1.1 mL)
- 2.3.3 5 mL Injection
- 2.4 Hydroxyprogesterone Caproate Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals Injection
- 2.4.3 Clinics Injection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hydroxyprogesterone Caproate Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hydroxyprogesterone Caproate Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Hydroxyprogesterone Caproate Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Hydroxyprogesterone Caproate Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Hydroxyprogesterone Caproate Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hydroxyprogesterone Caproate Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hydroxyprogesterone Caproate Injection, Product Type & Application
- 3.8 Global Manufacturers of Hydroxyprogesterone Caproate Injection, Established Date
- 3.9 Global Hydroxyprogesterone Caproate Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AMAG Pharmaceuticals
- 4.1.1 AMAG Pharmaceuticals Company Information
- 4.1.2 AMAG Pharmaceuticals Business Overview
- 4.1.3 AMAG Pharmaceuticals Hydroxyprogesterone Caproate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AMAG Pharmaceuticals Hydroxyprogesterone Caproate Injection Product Portfolio
- 4.1.5 AMAG Pharmaceuticals Recent Developments
- 4.2 Mcguff Pharmaceuticals Inc
- 4.2.1 Mcguff Pharmaceuticals Inc Company Information
- 4.2.2 Mcguff Pharmaceuticals Inc Business Overview
- 4.2.3 Mcguff Pharmaceuticals Inc Hydroxyprogesterone Caproate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mcguff Pharmaceuticals Inc Hydroxyprogesterone Caproate Injection Product Portfolio
- 4.2.5 Mcguff Pharmaceuticals Inc Recent Developments
- 4.3 Aspen Oss B.V
- 4.3.1 Aspen Oss B.V Company Information
- 4.3.2 Aspen Oss B.V Business Overview
- 4.3.3 Aspen Oss B.V Hydroxyprogesterone Caproate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Aspen Oss B.V Hydroxyprogesterone Caproate Injection Product Portfolio
- 4.3.5 Aspen Oss B.V Recent Developments
- 4.4 American Regent, Inc.
- 4.4.1 American Regent, Inc. Company Information
- 4.4.2 American Regent, Inc. Business Overview
- 4.4.3 American Regent, Inc. Hydroxyprogesterone Caproate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 American Regent, Inc. Hydroxyprogesterone Caproate Injection Product Portfolio
- 4.4.5 American Regent, Inc. Recent Developments
- 4.5 Mylan Institutional
- 4.5.1 Mylan Institutional Company Information
- 4.5.2 Mylan Institutional Business Overview
- 4.5.3 Mylan Institutional Hydroxyprogesterone Caproate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Institutional Hydroxyprogesterone Caproate Injection Product Portfolio
- 4.5.5 Mylan Institutional Recent Developments
5 Global Hydroxyprogesterone Caproate Injection Market Scenario by Region
- 5.1 Global Hydroxyprogesterone Caproate Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hydroxyprogesterone Caproate Injection Sales by Region: 2021-2032
- 5.2.1 Global Hydroxyprogesterone Caproate Injection Sales by Region: 2021-2026
- 5.2.2 Global Hydroxyprogesterone Caproate Injection Sales by Region: 2027-2032
- 5.3 Global Hydroxyprogesterone Caproate Injection Revenue by Region: 2021-2032
- 5.3.1 Global Hydroxyprogesterone Caproate Injection Revenue by Region: 2021-2026
- 5.3.2 Global Hydroxyprogesterone Caproate Injection Revenue by Region: 2027-2032
- 5.4 North America Hydroxyprogesterone Caproate Injection Market Facts & Figures by Country
- 5.4.1 North America Hydroxyprogesterone Caproate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hydroxyprogesterone Caproate Injection Sales by Country (2021-2032)
- 5.4.3 North America Hydroxyprogesterone Caproate Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hydroxyprogesterone Caproate Injection Market Facts & Figures by Country
- 5.5.1 Europe Hydroxyprogesterone Caproate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hydroxyprogesterone Caproate Injection Sales by Country (2021-2032)
- 5.5.3 Europe Hydroxyprogesterone Caproate Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hydroxyprogesterone Caproate Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hydroxyprogesterone Caproate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hydroxyprogesterone Caproate Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hydroxyprogesterone Caproate Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hydroxyprogesterone Caproate Injection Market Facts & Figures by Country
- 5.7.1 South America Hydroxyprogesterone Caproate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hydroxyprogesterone Caproate Injection Sales by Country (2021-2032)
- 5.7.3 South America Hydroxyprogesterone Caproate Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Hydroxyprogesterone Caproate Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hydroxyprogesterone Caproate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hydroxyprogesterone Caproate Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hydroxyprogesterone Caproate Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hydroxyprogesterone Caproate Injection Sales by Type (2021-2032)
- 6.1.1 Global Hydroxyprogesterone Caproate Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Hydroxyprogesterone Caproate Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Hydroxyprogesterone Caproate Injection Revenue by Type (2021-2032)
- 6.2.1 Global Hydroxyprogesterone Caproate Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hydroxyprogesterone Caproate Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Hydroxyprogesterone Caproate Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hydroxyprogesterone Caproate Injection Sales by Application (2021-2032)
- 7.1.1 Global Hydroxyprogesterone Caproate Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Hydroxyprogesterone Caproate Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Hydroxyprogesterone Caproate Injection Revenue by Application (2021-2032)
- 7.2.1 Global Hydroxyprogesterone Caproate Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hydroxyprogesterone Caproate Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Hydroxyprogesterone Caproate Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hydroxyprogesterone Caproate Injection Value Chain Analysis
- 8.1.1 Hydroxyprogesterone Caproate Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hydroxyprogesterone Caproate Injection Production Mode & Process
- 8.2 Hydroxyprogesterone Caproate Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hydroxyprogesterone Caproate Injection Distributors
- 8.2.3 Hydroxyprogesterone Caproate Injection Customers
9 Global Hydroxyprogesterone Caproate Injection Analyzing Market Dynamics
- 9.1 Hydroxyprogesterone Caproate Injection Industry Trends
- 9.2 Hydroxyprogesterone Caproate Injection Industry Drivers
- 9.3 Hydroxyprogesterone Caproate Injection Industry Opportunities and Challenges
- 9.4 Hydroxyprogesterone Caproate Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst